Although currently available anticoagulants are telling for the prevention and treatment of thromboembolic disorders, they assume several drawbacks. Low-molecular-weight heparins and fondaparinux might relieve oneself a predictable level of anticoagulation and requires no coagulation supervise; however, they must be given parenterally, which leave them to be awkward for long-term use. Vitamin K antagonists, warfarin, is administered vocally, but produce a versatile anticoagulant response because of intake vitamin K and multiple do drugs interactions affect their metabolism (Augoustides, (2011). Consequently, coagulation monitoring and frequent process adjustments are needed to ensure a therapeutic level of anticoagulation is reached. This is troublesome for patients and health care professionals, and costly for the healthcare system. These limitations have encouraged the development of new oral anticoagulants that target thrombin or factor Xa and can be given in frosty doses without coagulation monitoring. This paper focuses on a new oral anticoagulant rivaroxaban or xarelto.
Mechanism of Action
Rivaroxaban or xarelto prevents Factor Xa (FXa) at a central point in the coagulation cascade, where the external and intrinsic pathways meet, helping to modulate thrombin generation. Preventing thrombin generation helps to inhibit clog up formation. Xarelto does not require a cofactor, such as antithrombin 3 for activity. Based on the studies, rivaroxaban demonstrated selective inhibition of some(prenominal) free and clot-bound FXa as well as FXa in the factor X complex (XARELTO®, 2012).
Pharmacokinetics
Rivaroxaban, an oral direct Factor Xa inhibitor, is an active complicated that exhibits high oral bioavailability, approximately 80%, and a fast onset and offset of action. Plasma levels of rivaroxaban peak 23...If you hope to get a full essay, order it on our website: Ordercustompaper.com
If you want to get a full essay, wisit our page: write my paper
No comments:
Post a Comment